Insights on mid-term TAVR performance: 3-year clinical and echocardiographic results from the CoreValve ADVANCE study
Authors:
- For the ADVANCE Study InvestigatorsFIFor the ADVANCE Study Investigators
- Sabine BleizifferSBSabine Bleiziffer
- 8 May 2017
- journal article
- research article
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 106 (10) , 784-795
Abstract
Background Extensive evidence relating to transcatheter aortic valve replacement (TAVR) has accumulated in recent years, but mid-term outcomes are less reported. We investigated 996 patients after implantation of the CoreValve prosthesis for severe aortic stenosis in a real-world setting. Objective To report clinical and echocardiographic 3-year results from the ADVANCE study. Methods ADVANCE is a prospective, multicenter, fully monitored, nonrandomized clinical study. This analysis assessed valve-related events, predictors of early and mid-term mortality after TAVR, and systolic and diastolic prosthesis performance over 3 years. Results Three years after TAVR, the rate of major adverse cardiac/cerebrovascular events was 38.5%. All-cause mortality was 33.7%; cardiovascular mortality, 22.3%; VARC-1 stroke, 6.5%; and New York Heart Association class III/IV, 19.5%. Mean effective orifice area was consistently 1.7 cm2 from discharge to 3 years, and average mean aortic valve gradient remained ≤10 mmHg. At 3 years, 12.6% of patients had moderate and none had severe paravalvular regurgitation. Multivariable analysis identified Society of Thoracic Surgeons (STS) score, device migration, prior atrial fibrillation, and major vascular complication as predictors of early mortality. Predictors of mid-term mortality included male gender, STS score, history of chronic obstructive pulmonary disease, history of cancer, stroke, life-threatening/disabling or major bleeding, and valve deterioration. Conclusions Our 3-year data demonstrate significant hemodynamic benefits and durable symptom relief after CoreValve prosthesis implantation. Postprocedural patient management should be carefully considered, since postprocedural valve-related events were identified as independent predictors of mid-term mortality. Trial registration ClinicalTrials.gov, NCT01074658.Keywords
Funding Information
- Medtronic ((Funded the ADVANCE Study))
This publication has 35 references indexed in Scilit:
- Relation Between Clinical Best Practices and 6-Month Outcomes After Transcatheter Aortic Valve Implantation With CoreValve (from the ADVANCE II Study)The American Journal of Cardiology, 2017
- 3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve ReplacementJACC, 2016
- Year in reviewCurrent Opinion in Cardiology, 2016
- Causes and timing of death during long-term follow-up after transcatheter aortic valve replacementAmerican Heart Journal, 2014
- Long-Term Outcomes of Inoperable Patients With Aortic Stenosis Randomly Assigned to Transcatheter Aortic Valve Replacement or Standard TherapyCirculation, 2014
- Incidence, Predictors, and Outcomes of Aortic Regurgitation After Transcatheter Aortic Valve ReplacementJACC, 2013
- Beyond the short-term: Clinical outcome and valve performance 2 years after transcatheter aortic valve implantation in 227 patientsThe Journal of Thoracic and Cardiovascular Surgery, 2012
- Long-Term Outcomes After Transcatheter Aortic Valve Implantation in High-Risk Patients With Severe Aortic StenosisJACC, 2011
- Incidence and Predictors of Early and Late Mortality After Transcatheter Aortic Valve Implantation in 663 Patients With Severe Aortic StenosisCirculation, 2011
- Effect of Concomitant Coronary Artery Disease on Procedural and Late Outcomes of Transcatheter Aortic Valve ImplantationThe Annals of Thoracic Surgery, 2010